Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

Viewing Page 6 of 54 | Showing Results 26 - 30 of 266

A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)

Inclusion Criteria:•Age ≥18 years•Histologically or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB)...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

General Inclusion Criteria (all dose escalation and expansion cohorts):• Have histologically or cytologically confirmed locally advanced (and not a...

Min Sung Park, M.D.
  • Swedish Medical Center
Viewing Page 6 of 54 | Showing Results 26 - 30 of 266